Clinical trial NCT03472768: The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support
Official title: The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Respiratory Failure
Keywords: ECMO
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2018-03-21
Enrollment: 90
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Critically-ill children with respiratory failure requiring mechanical circulatory and/or respiratory support.

Brief summary: Newborns and children with life-threatening heart and lung failure may require support with ECMO (extracorporeal membrane oxygenation). With ECMO, oxygen and carbon dioxide are exchanged and circulated throughout the body even if the heart is unable to do so. Unfortunately, ECMO can cause breakdown of the red blood cells (known as hemolysis). For unclear reasons, newborns are at particularly high risk of hemolysis while being supported by ECMO. The amount of hemolysis is measured with concentrations of a breakdown product from red blood cells known as free hemoglobin. One possible reason for high free hemoglobin levels in newborns on ECMO could be related to another blood protein called haptoglobin. Haptoglobin is known to help in clearing free hemoglobin through the kidneys into the urine. However, haptoglobin levels in newborns can be very low and increases slowly during the first few months of life. Free hemoglobin may be inappropriately high in newborns supported by ECMO because of low levels of haptoglobin. The purpose of this study is to characterize haptoglobin, free hemoglobin, and hemolysis in newborns and children supported by ECMO and compare those values to age-matched newborns and children not on ECMO.


Eligibility criteria: Inclusion Criteria:

* ECMO group - Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. We will target enrollment of 15 subjects less than 12 months of age (with at least 10 subjects enrolled less than 6 months of age) and 15 subjects over 12 months of age. These targets are set to address the secondary aim in the context of normal adult-level haptoglobin concentrations reportedly achieved by 6-12 months of age.
* Age-matched control group - Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject. Age-matching will be performed by the following age groups:

  * Neonates 37-40 weeks gestation
  * Neonates 40-42 weeks gestation
  * Neonates 42-44 weeks gestation
  * Neonates 44-46 weeks gestation
  * Neonates 46-48 weeks gestation
  * Infants 2-4 months of age
  * Infants 4-6 months of age
  * Infants 6-12 months of age
  * Children 1-4 years of age
  * Children 4-8 years of age
  * Children 8-12 years of age
  * Children 12-18 years of age

Age-matched control subjects will proceed through the 3 total blood sample collections even if endotracheal extubation occurs within the 3 days of study participation. Age-matching is intended to collect a sample population comparable to the ECMO subject population. We will not match to gender.

Exclusion Criteria (both groups, ECMO and age-matched controls):

* Personal or family history of thrombotic, hemorrhagic, or hemolytic disease.
* Personal history of hematologic malignancy.
* Premature neonates less than 37-weeks gestation and/or less than 2 kg in weight.
* Infection will not be an excluding factor for either subject group.

Primary outcomes:
measure: Characterize the relationship between plasma haptoglobin and free hemoglobin levels in children supported by ECMO.
timeFrame: Daily for 7 days
measure: Characterize the relationship between plasma haptoglobin and free hemoglobin levels in children supported by ECMO.
timeFrame: 7 days
Secondary outcomes:
measure: Characterize the deficiency of plasma haptoglobin at birth.
timeFrame: Daily for 3 days
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado and the University of Colorado School of Medicine
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: John Kim, MD
role: PRINCIPAL_INVESTIGATOR
References: